Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shanghai Henlius Biotech, Inc. is extending its collaboration with Fosun Pharma and Jiangsu Wanbang to continue commercializing HANLIKANG and HANDAYUAN in China. The company plans to set new annual caps for the transactions under its existing agreements through 2027, in compliance with Hong Kong Stock Exchange requirements. This move aims to ensure sustained cooperation and meet regulatory standards for connected transactions.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- 3 Penny Stocks to Watch Now, 11/26/24
- Rivian Gets Conditional DOE Loan of $6.6B for Georgia Plant
- Tesla Stock Falls 4% on News of Exclusion from California EV Tax Rebates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
